Cavazzoni Helms US FDA Drug Center With OTC Monograph Reform Starting, Novel Switches Next
Woodcock Era At CDER Ends; Cavazzoni Named Permanent Director
Executive Summary
Patrizia Cavazzoni, who likely represents a somewhat different leadership style for CDER, distinguished herself while leading the center temporarily during the COVID-19 pandemic.
You may also be interested in...
FDA Neuroscience Director Dunn's Appearance At Tanezumab AdComm Confirms Neurology Office Is Intact
Dunn’s participation at the panel meeting ended speculation that he left the US FDA.
Gottlieb: No ‘Plan B’ If Woodcock Isn’t Nominated As US FDA Commissioner
Janet Woodcock would continue tackling issues including bogus COVID-19 claims and heavy metals in baby food if nominated as FDA commissioner, says former head Scott Gottlieb. He praises Woodcock’s “great judgment” and her view on policy that will “expand across the agency.”
US FDA’s Amy Abernethy Leaves Behind Legacy Of Tech Modernization, Real-World Data
After slightly more than two years as second-in-command, Abernethy tells the Pink Sheet she’s leaving FDA because the initiatives on which she was focused were starting to develop their own momentum. Abernethy, who also serves as the agency’s acting chief information officer, worked to modernize the FDA’s information technology infrastructure and data capabilities while also exploring ways to confidently use real-world data to support regulatory decision-making.